Multicenter, single-arm, phase II study of the trifunctional antibody catumaxomab (anti-EpCAM [epithelial cell adhesion molecule] x anti-CD3) administered intra- and postoperatively in patients with epithelial ovarian cancer

Trial Profile

Multicenter, single-arm, phase II study of the trifunctional antibody catumaxomab (anti-EpCAM [epithelial cell adhesion molecule] x anti-CD3) administered intra- and postoperatively in patients with epithelial ovarian cancer

Completed
Phase of Trial: Phase II

Latest Information Update: 16 Sep 2014

At a glance

  • Drugs Catumaxomab (Primary)
  • Indications Ovarian cancer
  • Focus Adverse reactions
  • Sponsors Neovii Biotech
  • Most Recent Events

    • 01 Aug 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 26 Aug 2008 Status change
    • 06 Aug 2008 Status change from recruiting to in progress as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top